Midi Health

Midi Health is revolutionizing women's midlife healthcare by addressing a critical clinical and market gap: while 77 million American women experience perimenopause or menopause annually, fewer than 20% of US OB-GYNs receive formal training in managing this life stage. Founded in 2021 by serial health entrepreneur Joanna Strober following her own struggle to access expert menopause care, Midi built a virtual clinic model combining three strategic innovations. First, the company developed evidence-based clinical protocols—led by world-renowned experts in women's midlife health—that trained nurse practitioners and physicians can deliver at scale, bypassing the shortage of menopause-trained specialists. Second, Midi pioneered an insurance-reimbursement model that removes the burden of direct-pay healthcare, contracting with major commercial insurance carriers (UnitedHealthcare, Cigna, Aetna) to cover consultations and medications. Third, the platform achieves nationwide scale, available across all 50 US states through both direct-to-consumer engagement and enterprise employer partnerships, positioning menopause care as a critical employee retention and diversity benefit.

The platform delivers comprehensive midlife health services: personalized care plans tailored to each patient's symptoms and health history; hormone replacement therapy and non-hormonal treatment options; blood and genetic testing for precision diagnosis; integrated mental health and sexual wellness support; lifestyle coaching; and a growing suite of evidence-based supplements. Importantly, Midi extends care beyond menopause-specific symptoms to address interconnected midlife health concerns: cardiovascular disease prevention, cancer survivorship, weight management (including GLP-1 medication protocols), sleep disorders, mood disorders, skin and hair health, and preventive longevity care through its AgeWell program. This holistic model reflects emerging clinical evidence that menopause represents a critical cardiovascular, metabolic, and cognitive health inflection point—not merely a hormonal event.

By February 2026, Midi had scaled to unicorn status ($1B+ valuation, $250M+ raised) serving 25,000+ women weekly with documented clinical outcomes: 28 percentage point increases in breast cancer screening adherence, 11 percentage point increases in colorectal cancer screening, and up to 13% reductions in total cost of care versus matched patient populations. The company's rapid ascent reflects both market validation and a shift in how venture capital, employers, and healthcare systems view women's health—no longer an afterthought, but a fundamental platform for driving healthcare equity, employee wellness, and clinical excellence.

Keywords: perimenopause, menopause, women's health, telehealth, virtual care, hormone replacement therapy, HRT, women's midlife health, digital health, healthcare accessibility, femtech, personalized medicine, employee benefits, preventive health, clinical outcomes, women's healthcare equity.